News

Targeted Oncology2d
Dr Srour Presents Promising Phase 1 Results for ALLO-316 in ccRCC
ALLO-316 shows promising results in advanced renal cell carcinoma, with a 25% response rate and rapid treatment turnaround, ...
New Clinical Findings Published in Scientific Journal Nature Validate LIXTE’s Ongoing Ovarian and Colorectal Cancer Trials
Article Indicates that Inhibition of PP2A Enhances Immunotherapy Responsewith LIXTE’s Proprietary Compound LB100 PASADENA, ...
New genetic marker linked to improved survival with immunotherapy in ovarian and other cancers
Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to have ...
News Medical on MSN8d
PPP2R1A mutations linked to improved survival in ovarian clear cell carcinoma
Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to have improved survival following immunotherapy compared to patients without ...